In 2015, the author of this article has published a first review on the patent landscape of antibody drug conjugate s (ADCs).[1](#ref-0001) Now, 10 years later, it is time for a wrap-up. While the basic principles discussed in that earlier article still apply, the ADC landscape has dramatically evolved and diversified in the meantime.